Antev Ltd.
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Private
- Established
- 2008-09-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.antev.co.uk
Teverelix Evaluated in Advanced Prostate Cancer
Phase 2
Completed
- Conditions
- Prostatic Adenoma
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Antev Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04693507
- Locations
- π±πΉ
Klaipeda University Hospital, Klaipeda, Lithuania
π±πΉNational Cancer Institute, Vilnius, Lithuania
π±πΉVilnius University Hospital Santaros Clinic, Vilnius, Lithuania
A Study of Parenterally-administered Teverelix TFA in Healthy Male Volunteers
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Antev Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03781947
- Locations
- π¬π§
PAREXEL International Early Phase Clinical Unit (EPCU), London, Middlesex, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath